Abstract
Electrocochleography was performed on three patients to monitor the intravenous administration of tobramycin. When peak serum tobramycin levels exceeded 8-10 mug/ml an immediate dramatic reduction in cochlear output was observed, which recovered fully as serum levels fell. The patients had no auditory or vestibular symptoms either during or after treatment.